UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2016
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
|
(State or other jurisdiction of |
|
|
001-35518 |
|
20-2590184 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1550 East Gude Drive, Rockville MD |
|
20850 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 19, 2016, Supernus Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The definitive proxy statement pertaining to the Annual Meeting was previously filed by the Company with the Securities and Exchange Commission on April 19, 2016. As of the close of business on March 22, 2016, there were 49,407,236 shares of common stock outstanding and entitled to vote. The tabulation of votes for each proposal voted on by the stockholders was as follows:
Proposal 1: Election of Class I Directors, each to serve until the Annual Meeting of the Company in 2019.
|
Name |
|
Votes For |
|
Votes Withheld |
|
Broker Non-Votes |
|
|
Jack A. Khattar |
|
35,681,511 |
|
768,112 |
|
379,525 |
|
|
M. James Barrett, Ph.D. |
|
13,329,960 |
|
23,119,663 |
|
379,525 |
|
|
William A. Nuerge |
|
35,569,357 |
|
880,266 |
|
379,525 |
|
Proposal 2: Ratification of the approval of the Second Amended and Restated 2012 Equity Incentive Plan to increase the number of shares available under the plan and to update the performance criteria for making awards.
|
Votes For |
|
Votes Against |
|
Abstain |
|
Broker Non-Votes |
|
|
19,834,525 |
|
16,005,650 |
|
609,448 |
|
379,525 |
|
Proposal 3: Ratification of the approval of the Second Amended and Restated 2012 Employee Stock Purchase Plan to increase the number of shares available under the plan.
|
Votes For |
|
Votes Against |
|
Abstain |
|
Broker Non-Votes |
|
|
35,504,333 |
|
347,000 |
|
598,290 |
|
379,525 |
|
Proposal 4: Ratification of the appointment of KPMG LLP as the Company’s independent public accounting firm for the fiscal year ending December 31, 2016.
|
Votes For |
|
Votes Against |
|
Abstain |
|
|
36,810,937 |
|
5,523 |
|
12,688 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
SUPERNUS PHARMACEUTICALS, INC. | ||
|
|
| ||
|
DATED: May 19, 2016 |
By: |
/s/ |
Gregory S. Patrick |
|
|
|
Gregory S. Patrick | |
|
|
|
Vice-President and Chief Financial Officer | |